Phio Pharma Insider Todd Buys 17,000 Shares on RSU Deal, Signaling Confidence Amid Volatile Stock and Dilution Concerns

Insider Buying Signals at Phio Pharmaceuticals

On September 28, 2026, senior executive Plott Ronald Todd executed a purchase of 17,000 shares of Phio’s common stock, adding to his post‑transaction holding of 32,000 shares. The shares were acquired at $0.00 because they represent unvested restricted stock units that will vest on the first anniversary of the grant. While the transaction itself is a “buy” with no cash outlay, it signals Todd’s confidence in the company’s near‑term trajectory. The buy aligns with a pattern of modest, regular acquisitions—his last purchase on August 19, 2026 added 15,000 shares at $1.14—suggesting a steady, long‑term stake rather than a quick speculative play.

What This Means for Investors

Phio’s share price has been volatile: a 3% weekly gain sits on top of a 5.5% monthly decline and a 57% yearly drop. The company’s price‑earnings ratio is negative, indicating limited profitability in the current period. Against this backdrop, Todd’s purchase—though small in dollar terms—adds weight to the “buy” sentiment reflected on social‑media channels, where buzz has spiked to nearly 200 % and sentiment remains neutral. For shareholders, this could be a sign that insiders believe the company’s recent 2020 Long‑Term Incentive Plan amendment, which now allows issuance of 2.45 million shares, will eventually drive value. However, the dilution risk from that reserve remains a concern; investors will need to monitor whether the plan’s activation aligns with revenue growth and clinical milestones.

A Profile of Plott Ronald Todd

Todd’s insider activity is characterized by disciplined, incremental purchases. His trades have always been “buy” orders, never sales, and have ranged from 15,000 to 17,000 shares per transaction, with no cash paid for the most recent trade. The pattern reflects a long‑term horizon—unvested RSUs that will only become liquid in a year—rather than immediate trading pressure. Unlike the CEO and CFO, who have engaged in large, sometimes volatile trades (e.g., Bitterman’s 400,000‑share purchase on September 28), Todd’s transactions appear risk‑averse and supportive of the company’s valuation. This conservative buying style suggests he views Phio as a steady, if slowly growing, biotech investment.

Industry Context and Future Outlook

Phio operates in the highly competitive cancer immunotherapy space, where clinical successes can trigger rapid stock swings. The recent 2026 annual meeting saw shareholders approve a substantial incentive plan expansion, potentially providing the company with additional capital to fund research without external debt. Todd’s buy, coupled with the CFO and CEO’s sizable purchases, indicates that top management remains optimistic about upcoming product candidates and regulatory approvals. For investors, the key will be to watch whether clinical data releases or partnership announcements lift the share price beyond the 52‑week high of $4.19, while also managing dilution from the expanded incentive pool.